@article{7e328d08046b4e8fb9f18b7791c2a631,
title = "10th Anniversary of the European Association for Predictive, Preventive and Personalised (3P) Medicine - EPMA World Congress Supplement 2020",
abstract = "In 2019, the EPMA celebrated its 10th anniversary at the 5th World Congress in Pilsen, Czech Republic. The history of the International Professional Network dedicated to Predictive, Preventive and Personalised Medicine (PPPM / 3PM) is rich in achievements. Facing the coronavirus COVID-19 pandemic it is getting evident globally that the predictive approach, targeted prevention and personalisation of medical services is the optimal paradigm in healthcare demonstrating the high potential to save lives and to benefit the society as a whole. The EPMA World Congress Supplement 2020 highlights advances in 3P medicine.",
author = "EPMA and Olga Golubnitschaja and Ondrej Topolcan and Radek Kucera and Vincenzo Costigliola and M. Akopyan and Akulov, {S. N.} and O. Alexandrova and Angel Alonso and Andrews, {Russell J.} and Duarte, {A. Assuane} and O. Azarova and Maximilian Babel and L. Babenko and A. Barilo and Baturin, {V. A.} and Joanna Bauer and Jan Baxa and Becker, {Karl Friedrich} and Zuzana Beckov{\'a} and I. Belenov and I. Belenova and Sergi Beltr{\'a}n and Peter Berek and Toya Bernad and Jaroslav Betka and Boshyan, {R. O.} and Nadiya Boyko and Paul Brennan and Christoph Brochhausen and Pavel Broz and Rostyslav Bubnov and Rosario Carmona and A. Cibisev and Renata Cifkova and Joaqu{\'i}n Dopazo and V. Drobnych and Vikt{\'o}ria Durajov{\'a} and Petr Duras and M. Eremin and I. Esaulenko and Gonzalo Etayo and Matthias Evert and M. Evsevyeva and Jiri Ferda and Eva Ferdova and A. FilinaL and Jan Filipovsky and Frolov, {V. A.} and Radka Fuchsova and M. Mozaffari",
note = "Funding Information: Supported by the Charles University Research Fund (Progres Q39), Charles University Research Centre program UNCE/MED/006 “University Center of Clinical and Experimental Liver Surgery”, European Regional Development Fund Project “Application of Modern Technologies in Medicine and Industry” (CZ.02.1.01/0.0/0.0/17_048/0007280) and by the National Sustainability Program I (NPU I) Nr. LO1503 by the Ministry of Education Youth and Sports of the Czech Republic. Funding Information: Supported by MH CZ-DRO (University Hospital Plzen-FNPl, 00669806); supported by the Charles University Research Fund (Progres Q39). Funding Information: Supported by the Health Development Agency of Czech Ministry of Health (project 15-27109), Charles University Research Fund (PROGRES, project Q39), by IDS Plc Boldon, UK, and by FNPl, 00669806. Funding Information: Acknowledgements Supported by a grant from the Ministry of Health of the CR – Conceptual Development of Research Organization Faculty Hospital in Pilsen – FNPI, 00669806. Funding Information: Biobanking is strongly supported by the European Commission and by a wide range of research and collaborative projects that are part of the biggest EU research and innovation program ever, Horizon 2020 [3]. The societal challenge of Horizon 2020 is {\textquoteleft}Health, demographic change and wellbeing (SC1){\textquoteright}. It is a call for - better Health and care, economic growth and sustainable health systems, with one of the priorities being {\textquoteleft}personalized medicine{\textquoteright} [4, 5, 6]. As biomedical research moves forward, there is a paradigm shift in medicine from a reactive to a proactive approach that is predictive, preventive, personalized and participatory [7]. Biobanking and major chronic illnesses have a global dimension. Globalization raises new ethical, legal and social (ELSI) questions as well as regulatory, technical and managerial questions [2, 3]. Currently, two international biobank entities: BBMRI-ERIC (Biobanking and BioMolecular resource Research Infrastructure - European Research Infrastructure Consortium) and ISBER (International Society for Biological and Environmental Repositories) are leading bodies in biobanking. Funding Information: Supported by Ministry of Health - Conceptual Development of research institutions 00669806, by the project CZ.1.05/2.1.00/03.0076 from European Regional Development Fund and Program Progress Q39 of the Charles University Prague. Funding Information: Supported by Charles University Research Fund (Progres Q39); MH CZ-DRO (University Hospital Plzen-FNPl, 00669806); National Sustainability Program I (NPU I) Nr. LO1503 provided byMEYS CZ. Funding Information: This project is supported by the University of Latvia Donor SIA “Mikrotīkls”. The University of Latvia Foundation administered this donation. Funding Information: This work was supported by the grant 16-15-00003 of the Russian Science Foundation. Funding Information: The BRoTHER (Biobank Research on Telemedical Approaches for Human Biobanks in a European Region) project is a bilateral, cross border collaboration between two regions: German-Bavaria and the Czech Republic. The project is supported by a grant from the Bavarian-Czech University Agency (BTHA) with funding coming from the Bavarian State Ministry of Finance. The aim of the project is to define and analyze the obstacles that must be overcome in order for two clinically related biobanks from two different national health care systems to set up collaboration. The BRoTHER consortium consists of four partners: two in Germany—the Institute of Pathology of the University of Regensburg and the Institute of Pathology at Munich{\textquoteright}s Technical University, and two in the Czech Republic—the Department of Immunochemistry at the Faculty Hospital in Pilsen and the Masaryk Memorial Cancer Institute of Masaryk University in Brno (Fig. 1). Publisher Copyright: {\textcopyright} 2020, The Author(s).",
year = "2020",
doi = "10.1007/s13167-020-00206-1",
language = "English (US)",
journal = "EPMA Journal",
issn = "1878-5077",
publisher = "BioMed Central",
}
